Immunotherapy of chronic myeloid leukemia: present state and future prospects
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
20635930
DOI
10.2217/imt.10.2
Knihovny.cz E-resources
- MeSH
- Immunotherapy, Active MeSH
- Antigens, Neoplasm administration & dosage immunology MeSH
- Fusion Proteins, bcr-abl immunology MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy immunology therapy MeSH
- Leukemia, Experimental immunology therapy MeSH
- Immunodominant Epitopes immunology MeSH
- Immunotherapy methods trends MeSH
- Clinical Trials as Topic MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Models, Immunological MeSH
- Mice MeSH
- Immunization Schedule MeSH
- Forecasting MeSH
- Antineoplastic Agents therapeutic use MeSH
- Cancer Vaccines administration & dosage therapeutic use MeSH
- Cell Line, Transformed MeSH
- Vaccination MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antigens, Neoplasm MeSH
- Fusion Proteins, bcr-abl MeSH
- Immunodominant Epitopes MeSH
- Antineoplastic Agents MeSH
- Cancer Vaccines MeSH
In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of CML, which has raised hopes that this disease may be curable by supplementing the current targeted chemotherapy with immunotherapeutic approaches. More than ten small-scale clinical trials have been carried out with experimental vaccines predominantly based on the p210bcr-abl fusion protein. Their results suggested beneficial effects in some patients. Recent data obtained in human patients as well as in animal models indicate that the p210bcr-abl protein does not carry the immunodominant epitope(s). These observations, combined with the recognition of an ever increasing number of other immunogenic proteins in CML cells, strongly support the concept that gene-modified, cell-based vaccines containing the full spectrum of tumor antigens might be the most effective immunotherapeutic approach. Recently created mathematical models have provided important leads for the timing of the combination of targeted drug therapy with vaccine administration. A strategy of how targeted drug therapy might be combined with vaccination is outlined.
References provided by Crossref.org
Kynurenine and uric acid levels in chronic myeloid leukemia patients
Antigens in chronic myeloid leukemia: implications for vaccine development
